TiSe2-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer

Libin Chen1,2,3, Wang Xue4,5, Jing Cao4,5

  • 1Department of Ultrasound in Medicine, Ningbo First Hospital, Ningbo, 315010, People's Republic of China.

Abstract

Insights

Titanium diselenide (TiSe2) nanosheets enhance sonodynamic therapy (SDT) for pancreatic cancer. Combining TiSe2-SDT with PD-1 blockade activates anti-tumor immunity, inhibiting tumor growth and metastasis.

Area of Science:

  • Biomedical Engineering
  • Materials Science
  • Oncology

Background:

  • Pancreatic cancer is a highly aggressive malignancy with limited treatment options.
  • Current immunotherapies for pancreatic cancer show promise but are hindered by poor T cell infiltration into tumors.

Purpose of the Study:

  • To investigate the efficacy of Titanium diselenide (TiSe2) nanosheets as a sonosensitizer for sonodynamic therapy (SDT).
  • To evaluate the combined therapeutic effect of TiSe2-mediated SDT and anti-PD-1 immune checkpoint blockade on pancreatic tumors and metastasis.

Main Methods:

  • Synthesis of stable Titanium diselenide (TiSe2) nanosheets.
  • Ultrasound (US) application to induce reactive oxygen species (ROS) generation for SDT.
  • Assessment of tumor-released tumor-associated antigens (TAAs), immunogenic cell death (ICD), dendritic cell (DC) maturation, T cell activation, and infiltration.
  • Combination therapy of TiSe2-SDT with anti-PD-1 blockade.

Main Results:

  • TiSe2 nanosheets effectively mediated SDT by generating ROS under hypoxic and normoxic conditions.
  • TiSe2-SDT induced ICD, promoting DC maturation and T cell activation and infiltration.
  • The combination of TiSe2-SDT and anti-PD-1 blockade significantly suppressed primary and distant tumor growth and prevented lung metastasis.
  • Enhanced systemic antitumor immune responses were observed, including increased CD8+ T cells and decreased regulatory T cells (Treg) in tumors.

Conclusions:

  • TiSe2 serves as an effective and safe sonosensitizer for SDT.
  • The combination of TiSe2-SDT and PD-1 blockade activates anti-tumor immunity via ICD induction, inhibiting tumor growth and metastasis.
  • This combination therapy presents a promising novel immunotherapy strategy for pancreatic cancer.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K